Dayna R Cenin1, D James B St John2, Melissa J N Ledger3, Terry Slevin4, Iris Lansdorp-Vogelaar5. 1. Education and Research, Cancer Council Western Australia, Perth, WA, Australia. dcenin@cancerwa.asn.au. 2. Cancer Prevention Centre, Cancer Council Victoria, Melbourne, VIC, Australia. 3. Education and Research, Cancer Council Western Australia, Perth, WA, Australia. 4. Cancer Council Western Australia, Perth, WA, Australia. 5. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: To estimate the impact of various expansion scenarios of the National Bowel Cancer Screening Program (NBCSP) on the number of bowel cancer deaths prevented; and to investigate the impact of the expansion scenarios on colonoscopy demand. DESIGN: MISCAN-Colon, a well established, validated computer simulation model for bowel cancer screening, was adjusted to reflect the Australian situation. In July 2013, we simulated the effects of screening over a 50-year period, starting in 2006. The model parameters included rates of participation in screening and follow-up, rates of identification of cancerous and precancerous lesions, bowel cancer incidence, mortality and the outcomes of the NBCSP. Five implementation scenarios, based on biennial screening using an immunochemical faecal occult blood test, were developed and modelled. A sensitivity analysis that increased screening participation to 60% was also conducted. PARTICIPANTS: Australian residents aged 50 to 74 years. MAIN OUTCOME MEASURES: Comparison of the impact of five implementation scenarios on the number of bowel cancer deaths prevented and demand for colonoscopy. RESULTS: MISCAN-Colon calculated that in its current state, the NBCSP should prevent 35 169 bowel cancer deaths in the coming 40 years. Accelerating the expansion of the program to achieve biennial screening by 2020 would prevent more than 70 000 deaths. If complete implementation of biennial screening results in a corresponding increase in participation to 60%, the number of deaths prevented will increase across all scenarios. CONCLUSIONS: The findings strongly support the need for rapid implementation of the NBCSP. Compared with the current situation, achieving biennial screening by 2020 could result in 100% more bowel cancer deaths (about 35 000) being prevented in the coming 40 years.
OBJECTIVES: To estimate the impact of various expansion scenarios of the National Bowel Cancer Screening Program (NBCSP) on the number of bowel cancer deaths prevented; and to investigate the impact of the expansion scenarios on colonoscopy demand. DESIGN: MISCAN-Colon, a well established, validated computer simulation model for bowel cancer screening, was adjusted to reflect the Australian situation. In July 2013, we simulated the effects of screening over a 50-year period, starting in 2006. The model parameters included rates of participation in screening and follow-up, rates of identification of cancerous and precancerous lesions, bowel cancer incidence, mortality and the outcomes of the NBCSP. Five implementation scenarios, based on biennial screening using an immunochemical faecal occult blood test, were developed and modelled. A sensitivity analysis that increased screening participation to 60% was also conducted. PARTICIPANTS: Australian residents aged 50 to 74 years. MAIN OUTCOME MEASURES: Comparison of the impact of five implementation scenarios on the number of bowel cancer deaths prevented and demand for colonoscopy. RESULTS: MISCAN-Colon calculated that in its current state, the NBCSP should prevent 35 169 bowel cancer deaths in the coming 40 years. Accelerating the expansion of the program to achieve biennial screening by 2020 would prevent more than 70 000 deaths. If complete implementation of biennial screening results in a corresponding increase in participation to 60%, the number of deaths prevented will increase across all scenarios. CONCLUSIONS: The findings strongly support the need for rapid implementation of the NBCSP. Compared with the current situation, achieving biennial screening by 2020 could result in 100% more bowel cancer deaths (about 35 000) being prevented in the coming 40 years.
Authors: Iris Vogelaar; Marjolein van Ballegooijen; Deborah Schrag; Rob Boer; Sidney J Winawer; J Dik F Habbema; Ann G Zauber Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: B Tran; C L Keating; S S Ananda; S Kosmider; I Jones; M Croxford; K M Field; R C Carter; P Gibbs Journal: Intern Med J Date: 2012-07 Impact factor: 2.048
Authors: Geoffrey Jalleh; Robert J Donovan; Chad Lin; Terry Slevin; Cassandra Clayforth; Iain S Pratt; Melissa Ledger Journal: Aust N Z J Public Health Date: 2010-04 Impact factor: 2.939
Authors: J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham Journal: Lancet Date: 1996-11-30 Impact factor: 79.321
Authors: P Colquhoun; H-C Chen; Jong Ik Kim; J Efron; E G Weiss; J J Nogueras; A M Vernava; S D Wexner Journal: Colorectal Dis Date: 2004-05 Impact factor: 3.788
Authors: Franka Loeve; Rob Boer; Ann G Zauber; Marjolein Van Ballegooijen; Gerrit J Van Oortmarssen; Sidney J Winawer; J Dik F Habbema Journal: Int J Cancer Date: 2004-09-10 Impact factor: 7.396
Authors: D Weller; D Coleman; R Robertson; P Butler; J Melia; C Campbell; R Parker; J Patnick; S Moss Journal: Br J Cancer Date: 2007-11-20 Impact factor: 7.640
Authors: Frank van Hees; Ann G Zauber; Harriët van Veldhuizen; Marie-Louise A Heijnen; Corine Penning; Harry J de Koning; Marjolein van Ballegooijen; Iris Lansdorp-Vogelaar Journal: Gut Date: 2015-06-10 Impact factor: 23.059
Authors: Douglas K Rex; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David Lieberman; Douglas J Robertson Journal: Am J Gastroenterol Date: 2017-06-06 Impact factor: 10.864
Authors: Elisabeth F P Peterse; Caroline B Osoro; Marc Bardou; Iris Lansdorp-Vogelaar Journal: Aliment Pharmacol Ther Date: 2021-03-08 Impact factor: 8.171
Authors: David B Preen; Iris Lansdorp-Vogelaar; Hooi C Ee; Cameron Platell; Dayna R Cenin; Lakkhina Troeung; Max Bulsara; Peter O'Leary Journal: Front Public Health Date: 2017-09-08
Authors: Joachim Worthington; Jie-Bin Lew; Eleonora Feletto; Carol A Holden; Daniel L Worthley; Caroline Miller; Karen Canfell Journal: PLoS One Date: 2020-02-03 Impact factor: 3.240
Authors: Maaike Alblas; Elisabeth F P Peterse; Mengmeng Du; Ann G Zauber; Ewout W Steyerberg; Nikki van Leeuwen; Iris Lansdorp-Vogelaar Journal: Cancer Med Date: 2021-09-12 Impact factor: 4.452
Authors: Sandra M E Geurts; Anne M W M Aarts; André L M Verbeek; Tony H H Chen; Mireille J M Broeders; Stephen W Duffy Journal: Epidemiol Health Date: 2022-01-03